Amedeo Azizi

Assoc. Prof.

Medical University of Vienna

Austria

Research Interests

Explore related searches

Professors in Austria

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Associate Professor Amedeo Azizi is a faculty member at the Medical University of Vienna, Austria. His research encompasses pediatric neuro-oncology, focusing on the management of neurofibromatosis type 1 and associated adverse events, cerebrospinal fluid distribution in brain tumor treatments, and innovative therapeutic strategies for pediatric central nervous system tumors. Recent articles highlight his contributions to clinical consensus guidelines and trial designs aimed at improving outcomes for children with various brain tumors.

Articles (26)

Alterations of the fibroblast growth factor (FGF) signalling pathway are increasingly recognized as frequent oncogenic drivers of paediatric brain tumours. We report on three patients treated with the selective FGFR1–4 inhibitor erdafitinib. Two patients were diagnosed with a posterior fossa ependymoma group A (PFA EPN) and one with a low‐grade glioma (LGG), harbouring FGFR3/FGFR1 overexpression and an FGFR1 internal tandem duplication (ITD), respectively. While both EPN patients did not respond to erdafitinib treatment, the FGFR1 ‐ITD‐harbouring tumour showed a significant decrease in tumour volume and contrast enhancement throughout treatment. The tumour remained stable 6 months after treatment discontinuation.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (16)

Muhammad Bilal

University Hospital Bonn

GERMANY

Amedeo Azizi

Research Interests

Explore related searches

Contact this professor

About

Articles (26)

Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients

Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors

Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas.

LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

Feasibility, tolerability, and first experience of intracystic treatment with peginterferon alfa-2a in patients with cystic craniopharyngioma

Neurofibromatosis type 1: screening form for children and adolescents in Austria: Consensus paper of the Austrian NF network,Neurofibromatose Typ 1: Vorsorgebogen für Kinder und Jugendliche in Österreich: Konsensuspapier des österreichischen NF-Netzwerks

Neurofibromatosis type 1 adult surveillance form for Austria

Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseases

Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions - International Pediatric Low-Grade Glioma Coalition

The telovelar approach for fourth ventricular tumors in children: is removal of the posterior arch of C1 necessary?

Proof-of-Concept for Liquid Biopsy Disease Monitoring of MYC-Amplified Group 3 Medulloblastoma by Droplet Digital PCR

Reply to: Comment on: Viral infections in pediatric brain tumor patients treated with targeted therapies

LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients.

Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.

Author Correction: A joint international consensus statement for measuring quality of survival for patients with childhood cancer.

Author Correction: A joint international consensus statement for measuring quality of survival for patients with childhood cancer.

A joint international consensus statement for measuring quality of survival for patients with childhood cancer.

Clinical applicability of miR517a detection in liquid biopsies of ETMR patients.

Placement of EVD in pediatric posterior fossa tumors: safe and efficient or old-fashioned? The Vienna experience.

Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors

Novel Insights into Diagnosis, Biology and Treatment of Primary Diffuse Leptomeningeal Melanomatosis

Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated <i>ROS1/NTRK</i>-Fusion Positive Pediatric High-Grade Glioma

Infiltrative gliomas of the thalamus in children: the role of surgery in the era of H3 K27M mutant midline gliomas.

Regarding "Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma".

NF1 optic pathway glioma. Analysing risk factors for visual outcome and indications to treat.

Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial.

Collaborators (16)

Muhammad Bilal

Thomas Czech

Berthold Pemp

Daniela Loetsch

Leonhard Müllauer

Uwe Fuhr

Rene Schmidt

Natalia Stepien

Andreas Peyrl

Hoong-Wei Gan

Miklós Garami

Thorsten Rosenbaum

Christian Dorfer

Ulrike Leiss

Johannes Gojo

Jacques Grill

Make your next move.